Delivery Order SPE2DB20D3303-SPE2DB24FY8S8

Award Date 1/31/24
Potential Completion Date 2/1/24
Potential Value $1.1K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of HEMABATE 250 MCG/ML AMPULML. The contract has a ceiling value of $4,239.50 and an ultimate completion date of July 8, 2025. The contract is not set aside and involves the delivery of a pharmaceutical product. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $2,666.41, is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product. The contract is a firm fixed-price delivery order with an ultimate completion date of April 18, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of HEMABATE 250 MCG/ML ampules. The award has a ceiling value of $2,686.73 and an ultimate completion date of August 9, 2024. The contract is not associated with any set-aside. AmerisourceBergen Drug Corp, a major pharmaceutical distributor, will provide the required medical supplies through this delivery order, which is part of a larger Indefinite Delivery...
This is a Firm Fixed Price Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of HEMABATE 250 MCG/ML AMPULML medical products. The contract has a ceiling value of $3,567.20 and an ultimate completion date of June 11, 2025. It is not designated as a set-aside contract. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a ceiling value of $1,921.55 and a period of performance through July 8, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a ceiling value of $1,656.93 and a performance period through May 28, 2025. The contract is not set-aside and was awarded on May 27, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite...
This federal contract award is a firm fixed price delivery order (SPE2DB20D1100|SPE2DB24FA8J4) issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a ceiling value of $12,900.22 and a performance period through March 21, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEMABATE 250 MCG/ML AMPULML, a medical product, with a ceiling value of $1,271.85 and a performance period ending on June 27, 2025. The contract is a firm fixed-price delivery order, without a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp...
This federal contract award, valued at $7,061.26, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of HEMABATE 250 MCG/ML AMPUL/ML, a pharmaceutical product, with a completion date of January 23, 2024. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, including the Department of Defense (DoD) and Veterans Affairs...
This federal contract award is for the delivery of HEMABATE 250 MCG/ML AMPUL/ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on December 6, 2024 with a ceiling value of $4,586.44. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of December 9, 2024. This award is not designated as a set-aside...
  • SPE2DB20D3303
    Indefinite Delivery Contract
  • SPE2DB20D3303-SPE2DB24FY8S8
    Delivery Order

This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is for the procurement of HEMABATE 250 MCG/ML AMPULML, a specialty pharmaceutical product, with a potential value of $1,097.24 and a completion date of February 1, 2024. This award is not associated with any set-aside designation. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver pharmaceutical products and medical supplies to DLA Troop Support Medical facilities supporting the Department of Defense.

Generated 5/1/24, 10:07 AM